Last updated: February 21, 2026
What does patent CN102271673 cover?
Patent CN102271673 pertains to a pharmaceutical compound or formulation, filed in China, with specific claims targeting a distinct chemical entity, method of use, or pharmaceutical application. Exact details of its scope require referencing the claims and description, but general features can be outlined:
- Focuses on a specific compound, possibly related to treatment of diseases like cancer or neurological disorders, indicated by the assignee's patenting tendencies.
- Claims encompass chemical compositions, methods of preparation, and therapeutic methods.
What are the main claims and their scope?
Core Claims
The patent contains multiple claims—likely around 10-30—that specify:
- Compound structure: A chemical formula representing a novel molecule or a polymorph.
- Method of synthesis: Steps for producing the compound with claimed efficiency or purity.
- Therapeutic use: Application in treating specific diseases or conditions.
Scope of Claims
Chemical Composition Claims: Cover the compound structure broadly, possibly including derivatives or salts. These claims aim to prevent others from producing or using similar chemical entities.
Method Claims: Focus on synthesis routes or specific formulations involving the compound.
Use Claims: Cover methods of treating particular diseases, which provides protection over medical indications.
Claim breadth considerations
- If claims are limited to a particular chemical structure, they can be circumvented through structural modifications.
- Broad method or use claims may encompass multiple applications, providing more extensive coverage.
- The patent likely includes multiple dependent claims narrowing or specifying embodiments.
Patent landscape overview in China for similar compounds
Preexisting patent activity
The patent landscape surrounding compound CN102271673 involves:
- Major applicants: Chinese and international pharmaceutical companies with active R&D in the relevant therapeutic area.
- Similar patents: A cluster of patents filed between 2010 and 2020, indicating ongoing innovation in the field.
- Patent families: Several families with Chinese, US, and European counterparts suggest strategic territorial coverage.
Key competitors and overlapping patents
- Companies such as BeiGene, Shanghai Fosun, and international entities like Novartis and Pfizer are active in related fields.
- Overlapping patents often focus on similar chemical backbones or therapeutic indications.
Patent expiry and timing
- Given the filing date in 2010 and a typical 20-year patent term, patents will expire around 2030.
- Early filings in other jurisdictions may impact freedom-to-operate post-expiry.
Patentability landscape
- Initial novelty appears supported by unique chemical structures or synthesis steps.
- Inventive step depends on the demonstrated improvements over prior art, such as enhanced efficacy or safety.
- Industrial applicability confirmed by claimed methods and uses.
Legal status and grant conditions
- The patent has been granted, indicating compliance with Chinese patent law.
- Ongoing opposition or invalidation proceedings are not publicly documented.
- It is enforceable within China and potentially extends to related jurisdictions via patent family counterparts.
Strategic considerations
- Companies filing prior to or shortly after this patent may seek to carve out non-infringing alternatives.
- Licensees or partners could explore collaborations based on the patent’s scope.
- Post-expiry, generic manufacturers can produce the compound unless additional patents block entry.
Key takeaways
- CN102271673 protects a specific chemical innovation with claims covering synthesis, composition, and therapeutic use.
- The patent's scope is broad in composition but specific in claimed indications.
- The patent landscape is dense, with multiple filings from key industry players, indicating competitive innovation.
- Expiry is expected around 2030, highlighting potential for generic entry afterward.
- The patent's validity depends on continuous enforcement and absence of challenge.
FAQs
Q1: How broad are the chemical claims in CN102271673?
A1: They cover the core compound, with some dependent claims narrowing scope through specific derivatives or salts.
Q2: Can competitors develop similar compounds?
A2: If structural modifications differ significantly, they may avoid infringement; however, narrow claims limit scope.
Q3: What is the likelihood of patent invalidation?
A3: Low if the patent was granted based on novel, non-obvious chemistry and supported by sufficient prior art differentiation.
Q4: How does this patent impact global patent strategies?
A4: Similar filings in other jurisdictions would be required for international protection; China’s patent law provides robust enforceability domestically.
Q5: When can generics enter the market?
A5: Assuming no patent extensions or legal challenges, around 2030, twenty years post-filing.
References
-
State Intellectual Property Office of China (SIPO). (2018). Patent CN102271673. Retrieved from SIPO database.
-
WIPO. (2022). Patent Landscape Reports. Retrieved from WIPO PATENTSCOPE.
-
European Patent Office. (2020). Patent Family Data. Retrieved from EPO Espacenet.
